Global Information
회사소개 | 문의 | 위시리스트

세계의 맞춤형 의료(Personalized Medicine) 시장

Personalized Medicines

리서치사 Global Industry Analysts, Inc.
발행일 2019년 05월 상품 코드 301518
페이지 정보 영문 313 Pages
가격
US $ 5,600 ₩ 6,833,000 PDF by E-mail (Single User License) help
DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로 1명만 이용할 수 있는 라이선스입니다. PDF 파일은 Copy & Paste 가 되지 않으며, 인쇄는 1회에 한해 가능합니다. 인쇄물 이용은 PDF 라이선스 소유자로 한정됩니다.
US $ 16,800 ₩ 20,499,000 PDF by E-mail (Global License to Company and its Fully-owned Subsidiaries) help
동일 기업 및 100% 자회사의 모든 분들이 이용할 수 있는 라이선스입니다. 이용 인원수 제한은 없습니다. PDF 파일은 Copy & Paste 가 가능합니다. 인쇄횟수에 제한은 없으나, 인쇄물의 이용 범위는 PDF 이용 범위에 준합니다.

주의 : 본 보고서는 DRM(디지털 저작권 관리 시스템)이 장착된 PDF 파일로, 라이선스에 따라 자료 이용 및 인쇄 등에 제약이 있을 수 있습니다. 자세한 내용은 라이선스 설명문( )을 참고하여 주시기 바랍니다.



세계의 맞춤형 의료(Personalized Medicine) 시장 Personalized Medicines
발행일 : 2019년 05월 페이지 정보 : 영문 313 Pages

세계의 맞춤형 의료(Personalized Medicine) 시장에 대해 조사 분석했으며, 부문별(표적치료, 시험/실험실 서비스), 지역별(미국, 캐나다, 일본, 유럽, 아시아태평양, 세계 기타 국가) 시장 분석, 향후 시장 예측, 과거 5년간 시장 분석, 주요 기업 개요 등의 정보를 정리하여 전해드립니다.

제1장 서론, 조사 방법, 제품 정의

제2장 주요 요약

  • 산업 개요
  • 시장 성장 촉진요인 및 억제요인
  • 시장 동향, 해결해야 할 과제
  • 제품 개요
    • 맞춤형 의료
    • 맞춤형 의료의 이점
    • 맞춤형 의료의 용도
    • 대장암
    • 혈전
    • 유방암
    • 맞춤형 의료에서의 진단
    • 유전자 검사
    • 동반진단
    • 유전자 검사
    • 유전자 검사의 종류
    • 프로테오믹스(Proteomics) : 중요한 Drug Discovery 툴
    • 프로테오믹스와 게노믹스 : 비교
  • 제품 도입과 승인
  • 주요 기업
  • 세계 시장 개요

제3장 시장

  • 미국
  • 캐나다
  • 일본
  • 유럽
    • 프랑스
    • 독일
    • 이탈리아
    • 영국
    • 유럽 기타 국가
  • 아시아태평양
  • 세계 기타 국가
LSH 18.03.29

이 페이지에 게재되어 있는 내용은 최신판과 약간 차이가 있을 수 있으므로 영문목차를 함께 참조하여 주시기 바랍니다. 기타 자세한 사항은 문의 바랍니다.

This report analyzes the worldwide markets for Personalized Medicines in US$ Million by the following Segments: Targeted Therapeutics, and Tests & Lab Services. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, and Rest of World. Annual estimates and forecasts are provided for the period 2016 through 2024. Also, a five-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 87 companies including many key and niche players such as -

Abbott Molecular, Inc.
Beckman Coulter Genomics
bioMerieux SA
Bristol-Myers Squibb Company
Dako Denmark A/S
F. Hoffmann-La Roche Ltd.

Table of Contents

I. INTRODUCTION, METHODOLOGY & PRODUCT DEFINITIONS

Study Reliability and Reporting Limitations

Disclaimers

Data Interpretation & Reporting Level

  • Quantitative Techniques & Analytics

Product Definitions and Scope of Study

  • Personalized Medicine

II. EXECUTIVE SUMMARY

1. INDUSTRY OVERVIEW

  • Access to Valuable Genetic Information Ushers Transformation in Medicine
  • Market Outlook
  • Adoption of Personalized Medicines - A Peek into Developed and Developing Economies
  • Increasing Market Availability of Personalized Medicines
  • Select Key Approved Personalized Medicines and Associated Biomarkers by Therapeutic Area
    • Table 1: Leading Personalized Medicines Worldwide (2015-2017): Annual Sales of Select Leading Medicines in US$ Million (includes corresponding Graph/Chart)
  • Constraints in Traditional Approach to Treatment Creates Need and Demand for Personalized Medicine
    • Table 2: Drug Ineffectiveness for Select Therapeutic Categories as a Percentage of Patient Population (includes corresponding Graph/Chart)
  • Economics of Personalized Medicine
  • Is Emergence of Personalized Medicine Signaling the End of Blockbusters?

2. MARKET DRIVERS AND RESTRAINTS

  • Growth Drivers in a Gist
  • Key Market Restraints
  • Increasing Incidence and Prevalence of CDDs: A Major Growth Driver
  • Oncology - A Major Application Market
  • Diagnosed Cases of Cancer on the Rise
  • World Cancer Statistics: Incidence and Mortality Data
    • Table 3: Global Cancer Incidence (2015): Number of New Cancer Cases in Thousands by Type and Gender (includes corresponding Graph/Chart)
    • Table 4: Global Cancer Mortality (2015): Number of Cancer Related Deaths in Thousands by Type and Gender (includes corresponding Graph/Chart)
  • Growing Cancer Cases in Developing Countries Bodes Well for the Personalized Medicine Market
  • Growing Importance of Personalized Drugs for Cancer Treatment
  • Ballooning Global Population Offers Significant Growth Opportunities
    • Table 5: World Population (In Million) for the Years 2018, 2022, 2025, 2030, 2035, 2040, 2045 and 2050 (includes corresponding Graph/Chart)
    • Table 6: Top 25 Countries Worldwide in Terms of Population: 2015 & 2016 (includes corresponding Graph/Chart)
  • Aging Global Population Drives Personalized Medicines
    • Table 7: Global Aging Population (in Thousands) by Age Group: 1975-2050 (includes corresponding Graph/Chart)
    • Table 8: Global Aging Population in Select Regions/Countries: Population of 60+ Individuals in '000s and as a Percentage of Total Population for 2015 & 2050 (includes corresponding Graph/Chart)
    • Table 9: Global Population Statistics for the 60+ Age Group by Region (2017) (includes corresponding Graph/Chart)
    • Table 10: Global Life Expectancy at Birth (Years) by Geographic Region: 1950-2050 (includes corresponding Graph/Chart)
    • Table 11: Life Expectancy for Select Countries in Number of Years: 2016 (includes corresponding Graph/Chart)
  • Increasing Healthcare Spending in Emerging Markets
    • Table 12: Healthcare Spending as a Percentage of GDP by Region (2016) (includes corresponding Graph/Chart)
    • Table 13: Per-Capita Healthcare Expenditure in US$ for Select Countries/Regions (2016) (includes corresponding Graph/Chart)
  • Changing Patients' Trends Drive Personalized Medicine
  • Technological Advancements and Consumer Push to Drive Personalized Medicine

3. MARKET TRENDS & ISSUES

  • Minimizing Adverse Events - A Major Benefit of Personalized Medicines
  • Personalized Medicines Brings Disease Prevention Closer to Reality
  • Ability to Manage Healthcare Costs Piques Industry and Government Alike
  • Potential to Uncover Additional Prospective Targets - A Major Benefit in Pursuit
  • Elimination of Invasive Tests Attracts Patients and Doctors towards Molecular Test-based Personalized Medicines
  • Genomics to Dictate Advancement of Personalized Medicines
  • Companion Diagnostics Drive Personalized Medicine
  • Biomarkers as Companion Diagnostics
  • Personalized Medicines Help Reducing R&D Costs
  • Personalized Medicine - A Corporate Growth Strategy
  • Development Pipeline Reveals Promising Picture for Personalized Medicine
  • Advancements in Biomedical Imaging to Enhance Personalized Medicines
  • Increasing Use of Personalized Medicines Drives Genetic Testing
  • Genetic Testing: The Rapidly Growing Segment of Molecular Diagnostics Market
  • Next-Generation Sequencing - A Giant Leap in Genome Sequencing
  • Single Nucleotide Polymorphism (SNP) - Making Advancements in Personalized Medicine
  • Personalized Medicine Goes Beyond DNA Analysis
  • Combination Approaches May Mark Future Endeavors
  • Need for New Designs in Clinical Trials Emerges in Therapies for Rare Cancers
  • Immunotherapy for Cancers - A Potential Breakthrough in the Sector
  • Personalized Medicine Industry - Inundated with Data
  • Advanced Computing Technologies - The Need of The Hour to Analyze Large Data
  • Artificial Intelligence Revolutionizing Personalized Medicine
  • Challenges Aplenty for Precision Medicine
  • Lack of Clinically Useful Diagnostic Tests - Growth Dampener
  • Pricing and Value Dilemma Haunts Personalized Medicines
  • Bedside Biopharmaceutical Production to Dramatically Reduce Cost of Personalized Medicine

4. PRODUCT OVERVIEW

  • Personalized Medicine
  • Benefits of Personalized Medicines
  • Few Applications of Personalized Medicine
  • Colorectal Cancer
  • Blood Clots
  • Breast Cancer
  • Diagnostics in Personalized Medicine
  • Genetic Tests
  • Companion Diagnostics
  • Genetic Testing
  • Types of Genetic Testing
    • Prenatal Diagnosis
    • Cancer Testing
    • Carrier Identification
    • Newborn Screening
    • Predictive Testing
    • Pre-Symptomatic Testing
    • Cytogenetic Tests
  • Proteomics: A Critical Drug Discovery Tool
  • Proteomics and Genomics: A Comparison

5. PRODUCT INTRODUCTIONS AND APPROVALS

  • Somalogic Teams Up with Leeds University for Personalized Medicines
  • University of Tokyo Sings Alliances for Developing Personalized Cancer Vaccine
  • Helomics and Ariel Ink Service Agreement to Commercialize PancreasDx Genomic Assay
  • Skyline Licenses Illumina's MiSeqDx(r) NGS Platform
  • Genoptix to Acquire Rosetta
  • DTU Bioinformatics Inks MoU with A*STAR
  • Bayer Inks Agreement with Loxo Oncology for Investigational Personalized Cancer Therapies
  • HealthSystem Joins Hands with Ambry Genetics to Advancing Precision Medicine Development
  • Invitrocue Establishes Joint Lab with A*STAR to Develop Personalized Medicine
  • OneOme and ProZed Partner to Bring Personalized Medicine to Canada
  • Insilico Medicine Launches ALS.AI Platform
  • Sysmex to Acquire Oxford Gene Technology
  • CVI to Partner with Panaceutics
  • Panaceutics Acquires Triangle Compounding Pharmacy
  • Acobiom Secures Funding from Bpifrance for OncoSNIPE(r) Project
  • Genospace Merges with Sarah Cannon
  • QNRF and QGP Launch Second Cycle of Path Towards Personalized Medicine
  • VieCure and Avera Team Up for Personalized Medicine
  • PierianDx Acquires Tute Genomics
  • iConquerMS Launches REAL MS(tm) Study
  • IntelliCyt Collaborates with NoTable Labs to Advance Predictive Personalized Medicine Platform
  • Thermo Fisher Partners with West China Hospital to Develop Precision Medicine
  • Swagene Introduces Personalized Medicine for Blood Cancer in Children
  • Macrogen Inks Joint Research Agreement with National Cancer Center Korea
  • Contextual Genomics Launches Phase II of Find It(tm) Genomics Test

6. FOCUS ON SELECT PLAYERS

  • Abbott Molecular, Inc. (USA)
  • Beckman Coulter Genomics (USA)
  • bioMerieux SA (France)
  • Bristol-Myers Squibb Company (USA)
  • Dako Denmark A/S (Denmark)
  • F. Hoffmann-La Roche Ltd. (Switzerland)
  • GlaxoSmithKline plc. (UK)
  • Hologic, Inc. (USA)
  • Lab 21 Limited (UK)
  • Macrogen, Inc. (Korea)
  • NeoGenomics Laboratories, Inc. (USA)
  • Novartis AG (Switzerland)
  • QIAGEN NV (The Netherlands)
  • Rosetta Genomics Ltd (Israel)
  • Thermo Fisher Scientific Inc. (USA)

7. GLOBAL MARKET PERSPECTIVE

    • Table 14: World Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 15: World Historic Review for Personalized Medicines by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 16: World 14-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)
  • By Segment
    • Table 17: World Recent Past, Current and Future Analysis for Targeted Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 18: World Historic Review for Targeted Therapeutics by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 19: World 14-Year Perspective for Targeted Therapeutics by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)
    • Table 20: World Recent Past, Current and Future Analysis for Tests & Lab Services for Personalized Medicine by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 21: World Historic Review for Tests & Lab Services for Personalized Medicine by Geographic Region - US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 22: World 14-Year Perspective for Tests & Lab Services for Personalized Medicine by Geographic Region - Percentage Breakdown of Revenues for US, Canada, Japan, Europe, Asia-Pacific (excluding Japan) and Rest of World Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

III. MARKET

1. THE UNITED STATES

  • A. Market Analysis
    • Outlook
    • US Individualized Medicine Market to Witness Significant Growth
    • Companies and Investors Bullish on Personalized Medicine Market in the US
    • Government Agencies Push for Personalized Medicines
    • Personalized Medicine Regulations in the FDA - Changing for the Better
    • FDA Approvals of Personalized Medicines Continue to Rise
      • FDA Approved Personalized Medicines: 2016 & 2017
      • FDA Approval of Keytruda to Stimulate Personalized Medicine Development
      • Challenges for FDA in Approving Personalized Drugs
    • Increasing Burden of Chronic Diseases Drives Focus onto Personalized Treatment
      • Cancer Statistics in the US
    • Table 23: New Cancer Cases by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)
    • Table 24: Cancer Related Deaths by Gender and Affected Site in the US (2017E) (includes corresponding Graph/Chart)
    • Table 25: New Cancer Cases in the US by State (2017E) (includes corresponding Graph/Chart)
    • Table 26: Number of Deaths Related to Major Types of Cancer in US by State: 2017E (includes corresponding Graph/Chart)
    • Impending Patient Cliff to Drive Opportunities for Personalized Medicine
    • Personalized Medicine Creating Opportunities for Diagnostics Testing Services
    • Molecular Diagnostics: Promising Growth Opportunities
    • Genetic and Genomic Clinical Lab Testing Market: Promising Prospects
    • Personalized Marketing Key to Growth in Personalized Medicines Market
    • Growing Efforts behind Brining AI into Medicine
    • Challenges Persist for the Personalized Medicine Market
    • Strategic Corporate Developments
    • Select Players
  • B. Market Analytics
    • Table 27: The US Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 28: The US Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 29: The US 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

2. CANADA

  • A. Market Analysis
    • Outlook
    • Rising Incidence of Chronic Diseases Spurs Need for Personalized Medicines
    • Table 30: New Cancer Cases in Canada (2017E): Breakdown of Cancer Incidence by Gender and Affected Site (includes corresponding Graph/Chart)
    • Table 31: New Cancer Cases in Canada by Province: 2017E (includes corresponding Graph/Chart)
    • Table 32: New Cancer Cases in Canada by Age Group: 2017E (includes corresponding Graph/Chart)
    • Table 33: Cancer Related Deaths in Canada (2017E): Percentage Breakdown of Number of Deaths by Gender and Affected Site (includes corresponding Graph/Chart)
    • Strategic Corporate Developments
  • B. Market Analytics
    • Table 34: Canadian Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 35: Canadian Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 36: Canadian 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

3. JAPAN

  • A. Market Analysis
    • Outlook
    • Demographics Drive Market Growth
    • Table 37: Japanese Population by Age Group (2017E): Percentage Breakdown for 0-14 Years, 15-24 Years, 25-54 Years, 55-64 Years, 64 Years and Above (includes corresponding Graph/Chart)
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 38: Japanese Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 39: Japanese Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 40: Japanese 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4. EUROPE

  • A. Market Analysis
    • Outlook
    • European Personalized Medicine Market to Exhibit Robust Growth
    • Aging Population to Drive Demand for Personalized Medicines
    • Table 41: EU-28 Country-wise Statistics of 65+ Population as % of Total Population: 2016 (includes corresponding Graph/Chart)
    • Insight into Molecular Diagnostics Markets in Europe
    • Regulatory Scenario in Europe for Companion Diagnostics
      • Companion Diagnostics: Select European Players with Strong Biomarker Pipeline
    • The Need for Improving Reimbursement Policies
    • Europe Heading towards Massive Improvements in Personalized Medicine
    • Personalized Medicine Big on EU Agenda - A Peek into EC Investments in This Space
  • B. Market Analytics
    • Table 42: European Recent Past, Current and Future Analysis for Personalized Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 43: European Historic Review for Personalized Medicines by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 44: European 14-Year Perspective for Personalized Medicines by Geographic Region - Percentage Breakdown of Revenues for France, Germany, Italy, UK and Rest of Europe Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)
    • Table 45: European Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 46: European Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 47: European 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4a. FRANCE

  • A. Market Analysis
    • Outlook
    • Strategic Corporate Development
    • biomerieux SA - A Key Player
  • B. Market Analytics
    • Table 48: French Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 49: French Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 50: French 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4b. GERMANY

  • A. Market Analysis
    • Outlook
    • Strategic Corporate Development
  • B. Market Analytics
    • Table 51: German Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 52: German Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 53: German 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4c. ITALY

  • Market Analysis
    • Table 54: Italian Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 55: Italian Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 56: Italian 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4d. THE UNITED KINGDOM

  • A. Market Analysis
    • Outlook
    • Initiatives Supporting the Personalized Medicine Market
    • Strategic Corporate Development
    • Select Players
  • B. Market Analytics
    • Table 57: UK Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 58: UK Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 59: UK 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

4e. REST OF EUROPE

  • A. Market Analysis
    • Outlook
    • Spain - Poised to become a Reckoning Force in Personalized Medicines
    • Slovenia - Moving Ahead with Use of Supercomputing in Managing Genetic Data
    • Select Players
  • B. Market Analytics
    • Table 60: Rest of Europe Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 61: Rest of Europe Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 62: Rest of Europe 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

5. ASIA-PACIFIC

  • A. Market Analysis
    • Outlook
    • Healthcare Spending in Asia-Pacific: On the Rise
    • China and India: Two Fast-Growing Markets
    • Focus on Select Region
      • India
      • Growing Investments in Pharmacogenomics Research Drives Personalized Medicine
      • Challenges Ahead...
    • Strategic Corporate Developments
    • Macrogen, Inc. (Korea) - A Key Player
  • B. Market Analytics
    • Table 63: Asia-Pacific Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 64: Asia-Pacific Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 65: Asia-Pacific 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)

6. REST OF WORLD

  • A. Market Analysis
    • Outlook
    • Strategic Corporate Development
    • Rosetta Genomics Ltd (Israel) - A Key Player
  • B. Market Analytics
    • Table 66: Rest of World Recent Past, Current and Future Analysis for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2016 through 2024 (includes corresponding Graph/Chart)
    • Table 67: Rest of World Historic Review for Personalized Medicines by Segment - Targeted Therapeutics and Tests & Lab Services Markets Independently Analyzed with Annual Revenue Figures in US$ Million for Years 2011 through 2015 (includes corresponding Graph/Chart)
    • Table 68: Rest of World 14-Year Perspective for Personalized Medicines by Segment - Percentage Breakdown of Revenues for Targeted Therapeutics and Tests & Lab Services Markets for Years 2011, 2017 and 2024 (includes corresponding Graph/Chart)
Back to Top
전화 문의
F A Q